Post-ERCP Acute Pancreatitis Clinical Trial
Official title:
Effectiveness of Thoracic Epidural Analgesia for the Prevention of Post-ERCP Pancreatitis
For 40 years, the post-ERCP (endoscopic retrograde cholangiopancreatography) pancreatitis has been the most frequent adverse effect of endoscopic transpapillary interventions. We sought to determine the efficacy of thoracic epidural analgesia for the prevention of post-ERCP pancreatitis. Between 2008 and 2013, a randomized study of the results of endoscopic treatment of 491 patients was conducted. The first group of patients (N=247) received thoracic epidural analgesia (TEA) during ERCP procedures, the patients of the second group (N=244) received a narcotic analgesic. To detect statistically significant differences between research groups adjusted odds ratios (OR) and their 95% confidence interval (CI) were calculated.
Preoperatively the subjects were randomly assigned (by using sealed envelopes - blind randomization) into two groups, 250 patients each. The patients of the first group had TEA applied during the ERCP procedure; other methods of pain relief were applied to the patients of the second (control) group. The first group (TEA group) of patients received the following premedication: atropine sulfate 0.5-1 mg, midazolan 5 mg. The puncture and catheterization of the epidural space was carried out according to standard procedure between thoracic vertebrae VII-VIII. Half an hour before performing ERCP ropivacaine 0.5% -10 ml. was injected into the epidural space. The second group (control group) of patients received the following premedication: atropine sulfate 0.5 -1 mg, midazolan 5 mg, trimeperidine 2% -1 ml. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546867 -
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
|
N/A | |
Terminated |
NCT02241512 -
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
|
Phase 2 | |
Completed |
NCT00222092 -
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
|
Phase 4 | |
Completed |
NCT05310409 -
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
|
||
Not yet recruiting |
NCT06260878 -
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT04770857 -
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
|
||
Completed |
NCT02641561 -
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
|
Phase 3 | |
Active, not recruiting |
NCT04145336 -
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
|
N/A | |
Completed |
NCT03629600 -
Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03756116 -
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
|
N/A | |
Recruiting |
NCT05664074 -
Rectal Indomethacin vs Intravenous Ketorolac
|
Phase 4 | |
Completed |
NCT02308891 -
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05336630 -
Study of Forceps Cannulation During ERCP
|
N/A | |
Recruiting |
NCT05857514 -
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05267379 -
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
|
||
Recruiting |
NCT05947461 -
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
|
N/A | |
Completed |
NCT03098082 -
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT02830984 -
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
|
N/A | |
Recruiting |
NCT02839356 -
Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Completed |
NCT01673763 -
Post-ERCP Pancreatitis Prevention by Stent Insertion
|
N/A |